Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.38 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.33 |
| ▸ | APAF1 | O14727 | 1/20 | 0.33 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7008476 | 0.80 | HTT (0.39) | HTTKMT2ADYRK1ACYP1A2CYP2C19 | |
| SCHEMBL1141394 | 0.77 | HTT (0.36) | HTTKMT2ADYRK1ACYP1A2CYP2C19 | |
| SCHEMBL1932691 | 0.77 | HTT (0.36) | HTTKMT2ADYRK1ANR4A2SOS2 | |
| SCHEMBL12629421 | 0.77 | CCR1 (0.45) | KMT2ANCF1NR4A2SOS2CYP1A2 | |
| SCHEMBL2211921 | 0.73 | MAPT (0.42) | KMT2ADYRK1AMAPTALDH1A1MEN1 | |
| SCHEMBL2210452 | 0.73 | PDE7A (0.37) | HTTKMT2ADYRK1ACYP1A2CYP2C19 | |
| SCHEMBL16432308 | 0.73 | NOS3 (0.46) | DYRK1ACYP1A2CYP2C19BACE1AURKA | |
| SCHEMBL29157221 | 0.71 | HTT (0.47) | HTTKMT2ADYRK1AALKCHEK1 | |
| SCHEMBL435803 | 0.71 | NR4A2 (0.61) | HTTNCF1NR4A2SOS2CYP1A2 | |
| SCHEMBL31285386 | 0.71 | NR4A2 (0.61) | HTTNCF1NR4A2SOS2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090589-A1 | HETEROCYCLIC HBS1L DEGRADERS | TANGO THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-2504336-B1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | ÆTERNA ZENTARIS GMBH (DE) | 2016-03-30 | — | — | EP | disclosed |
| EP-2504336-B1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | ÆTERNA ZENTARIS GMBH (DE) | 2016-03-30 | — | — | EP | disclosed |
| US-8461178-B2 | Naphthyridine derivatives and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2013-06-11 | — | — | US | disclosed |
| US-8461178-B2 | Naphthyridine derivatives and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2013-06-11 | — | — | US | disclosed |
| US-8461178-B2 | Naphthyridine derivatives and the use thereof as kinase inhibitors | AETERNA ZENTARIS GMBH (DE) | 2013-06-11 | — | — | US | disclosed |
| EP-2504336-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | Æterna Zentaris GmbH (DE) | 2012-10-03 | — | — | EP | disclosed |
| US-20110150831-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | AETERNA ZENTARIS GMBH (DE) | 2011-06-23 | — | — | US | disclosed |
| US-20110150831-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | AETERNA ZENTARIS GMBH (DE) | 2011-06-23 | — | — | US | disclosed |
| US-20110150831-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | AETERNA ZENTARIS GMBH (DE) | 2011-06-23 | — | — | US | disclosed |
| EP-2332939-A1 | Novel Naphthyridine derivatives and the use thereof as kinase inhibitors | Æterna Zentaris GmbH (DE) | 2011-06-15 | — | — | EP | disclosed |
| EP-2332939-A1 | Novel Naphthyridine derivatives and the use thereof as kinase inhibitors | Æterna Zentaris GmbH (DE) | 2011-06-15 | — | — | EP | disclosed |
| WO-2011064250-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | ÆTERNA ZENTARIS GMBH (DE) | 2011-06-03 | — | — | WO | disclosed |
| WO-2011064250-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | ÆTERNA ZENTARIS GMBH (DE) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150831-A1 | NOVEL NAPHTHYRIDINE DERIVATIVES AND THE USE THEREOF AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K2 | HTT 4710/4885KMT2A 3770/4885DYRK1A 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.